Private Management Group Inc. Has $13.16 Million Holdings in Bausch Health Cos Inc. $BHC

Private Management Group Inc. lifted its position in shares of Bausch Health Cos Inc. (NYSE:BHC) by 16.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,892,895 shares of the company’s stock after purchasing an additional 271,170 shares during the quarter. Private Management Group Inc. owned approximately 0.51% of Bausch Health Cos worth $13,156,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also bought and sold shares of BHC. Northwestern Mutual Wealth Management Co. boosted its stake in Bausch Health Cos by 6,661.3% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock valued at $35,000 after buying an additional 5,329 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in Bausch Health Cos by 65.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock valued at $51,000 after buying an additional 3,106 shares in the last quarter. Camelot Portfolios LLC acquired a new stake in Bausch Health Cos in the 4th quarter valued at $59,000. Dynamic Technology Lab Private Ltd acquired a new stake in Bausch Health Cos in the 1st quarter valued at $68,000. Finally, Concurrent Investment Advisors LLC acquired a new stake in Bausch Health Cos in the 4th quarter valued at $70,000. Institutional investors and hedge funds own 78.65% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on BHC shares. Royal Bank Of Canada decreased their price target on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a research note on Monday, April 27th. Weiss Ratings lowered Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 4th. Barclays decreased their price target on Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 25th. Finally, Wall Street Zen lowered Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research note on Sunday, February 15th. Four equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $8.00.

Insider Transactions at Bausch Health Cos

In other Bausch Health Cos news, Director Frank D. Lee sold 24,456 shares of Bausch Health Cos stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $5.43, for a total value of $132,796.08. Following the completion of the transaction, the director owned 49,339 shares in the company, valued at approximately $267,910.77. The trade was a 33.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 20.67% of the company’s stock.

Bausch Health Cos Trading Up 0.1%

Shares of BHC opened at $5.16 on Friday. The stock has a fifty day moving average price of $5.47 and a two-hundred day moving average price of $5.99. The company has a debt-to-equity ratio of 54.68, a quick ratio of 0.97 and a current ratio of 1.32. Bausch Health Cos Inc. has a 52-week low of $4.93 and a 52-week high of $8.69. The company has a market cap of $1.93 billion, a price-to-earnings ratio of -1.59 and a beta of 0.40.

Bausch Health Cos (NYSE:BHC) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $0.78 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.81 by ($0.03). Bausch Health Cos had a negative net margin of 11.47% and a negative return on equity of 2,922.77%. The business had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.37 billion. Analysts predict that Bausch Health Cos Inc. will post 4.08 EPS for the current fiscal year.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.